{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:59:56Z","timestamp":1790449196651,"version":"4.1.0"},"reference-count":11,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,10,29]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>A 50-year-old woman was referred to rheumatology for new onset polyarthralgia and headache. She had a history of metastatic lung adenocarcinoma and was started on treatment with the programmed death 1 receptor (PD-1) antagonist pembrolizumab 2\u2009months prior. Examination revealed left temporal artery tenderness and hand synovitis. Investigations revealed enlarged temporal artery on ultrasound imaging. On steroid treatment, she had resolution of symptoms, but due to significant steroid side effects required methotrexate and her PD-1 antagonist therapy was continued in consultation with her oncologist. Her malignant disease has remained stable, and she has improved functional status.<\/jats:p>","DOI":"10.1136\/bcr-2021-246443","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T09:40:44Z","timestamp":1638178844000},"page":"e246443","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Giant cell arteritis associated with PD-1 inhibition"],"prefix":"10.1136","volume":"14","author":[{"given":"Nina","family":"Couette","sequence":"first","affiliation":[{"name":"Rheumatology & Immunology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-2138","authenticated-orcid":false,"given":"Jisna","family":"Paul","sequence":"additional","affiliation":[{"name":"Rheumatology & Immunology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"2025082713092764000_14.11.e246443.1","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/annonc\/mdx306","article-title":"An unknown reaction to pembrolizumab: giant cell arteritis","volume":"28","author":"Micaily","year":"2017","journal-title":"Ann Oncol"},{"key":"2025082713092764000_14.11.e246443.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2020.100891","article-title":"Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma","volume":"20","author":"Narala","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2025082713092764000_14.11.e246443.3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","article-title":"Diagnosis and management of rare immune-related adverse events","volume":"25","author":"Schoenfeld","year":"2020","journal-title":"Oncologist"},{"key":"2025082713092764000_14.11.e246443.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1616848114"},{"key":"2025082713092764000_14.11.e246443.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190084"},{"key":"2025082713092764000_14.11.e246443.6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/acr.24632","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025082713092764000_14.11.e246443.7","first-page":"171148","article-title":"The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes","volume":"17","author":"Chang","year":"1990","journal-title":"J Rheumatol"},{"key":"2025082713092764000_14.11.e246443.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212649"},{"key":"2025082713092764000_14.11.e246443.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex461."},{"key":"2025082713092764000_14.11.e246443.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes153"},{"key":"2025082713092764000_14.11.e246443.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171428"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-246443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:09:34Z","timestamp":1756325374000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-246443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":11,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bcr-2021-246443"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-246443","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}